Tracker › Companies › EyePoint, Inc.
6 No sign of it. We found no public evidence tying EyePoint, Inc.'s cuts to AI.
Every tracked 2026 layoff at EyePoint, Inc., newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 6/100 (Minimal) · 80% interval 4–7 · evidence grade D · US · Instruments / Medical Devices
Stated reason: On October 17, 2026, following review of topline results from LUCIA, the second pivotal Phase 3 clinical trial evaluating DURAVYU™ for the treatment of wet age-related macular degeneration (wet AMD), the Board of Directors of the Company approved a strategic prioritization plan (the “Prioritization”) designed to reduce operating expenses and focus resources on the Company’s late-stage program for DURAVYU™ in diabetic…
Why 6: Cost-cutting / efficiency · Drivers: industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.608, industry exposure 0.712, AI investment 0.0, contrary evidence 0.0 · named roles: Computer and Information Systems Managers, General and Operations Managers, Nursing Assistants, Registered Nurses
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 4,500 workers
Health Care & Pharma · 718 workers
Health Care & Pharma · 628 workers
Health Care & Pharma · 278 workers
Health Care & Pharma · 145 workers
Health Care & Pharma · 130 workers
